Moreover, the underlying molecular mechanism suggests that mTOR inhibitors, such as rapamycin, may be promising drugs for NPRL3-related epilepsy, due to the abnormal activation of the mTOR signaling pathway caused by NPRL3 gene variation (8, 23, 24). Here, MTOR is linked to epilepsy.